|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q82838194
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010856.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q82838194
|
|
024
|
|
|
‡a
0000-0001-6516-2172
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q82838194
|
|
100
|
0 |
|
‡a
Ana Eugenia Rodríguez-Vicente
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Ana Eugenia Rodríguez-Vicente
‡c
wetenschapper
‡9
nl
|
|
400
|
0 |
|
‡a
Ana Eugenia Rodríguez-Vicente
‡c
investigador
‡9
es
|
|
670
|
|
|
‡a
Author's A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.
|
|
670
|
|
|
‡a
Author's A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia
|
|
670
|
|
|
‡a
Author's A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.
|
|
670
|
|
|
‡a
Author's aCGH-MAS: analysis of aCGH by means of multiagent system.
|
|
670
|
|
|
‡a
Author's ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
|
|
670
|
|
|
‡a
Author's Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia
|
|
670
|
|
|
‡a
Author's Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
|
|
670
|
|
|
‡a
Author's Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications
|
|
670
|
|
|
‡a
Author's CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
|
|
670
|
|
|
‡a
Author's DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains
|
|
670
|
|
|
‡a
Author's From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct
|
|
670
|
|
|
‡a
Author's Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
|
|
670
|
|
|
‡a
Author's Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.
|
|
670
|
|
|
‡a
Author's Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL.
|
|
670
|
|
|
‡a
Author's Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling
|
|
670
|
|
|
‡a
Author's Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression
|
|
670
|
|
|
‡a
Author's Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.
|
|
670
|
|
|
‡a
Author's MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL.
|
|
670
|
|
|
‡a
Author's MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.
|
|
670
|
|
|
‡a
Author's Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14.
|
|
670
|
|
|
‡a
Author's NEMHESYS-European Perspective on the Implementation of Next-generation Sequencing Into Clinical Diagnostics
|
|
670
|
|
|
‡a
Author's Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.
|
|
670
|
|
|
‡a
Author's Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.
|
|
670
|
|
|
‡a
Author's Personalized medicine into health national services: barriers and potentialities
|
|
670
|
|
|
‡a
Author's Pharmacogenetics and pharmacogenomics as tools in cancer therapy
|
|
670
|
|
|
‡a
Author's TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations.
|
|
670
|
|
|
‡a
Author's The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index
|
|
909
|
|
|
‡a
(orcid) 0000000165162172
‡9
1
|
|
919
|
|
|
‡a
lowfrequencyoflossesin11qchromosomeisassociatedwithbetteroutcomeandlowerrateofgenomicmutationsinpatientswithchroniclymphocyticleukemia
‡A
A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.
‡9
1
|
|
919
|
|
|
‡a
acghmasanalysisofacghbymeansofmultiagentsystem
‡A
aCGH-MAS: analysis of aCGH by means of multiagent system.
‡9
1
|
|
919
|
|
|
‡a
atmmutationratherthanbirc3deletionandormutationpredictsreducedsurvivalin11qdeletedchroniclymphocyticleukemiadatafromtheuklrfcll4trial
‡A
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
‡9
1
|
|
919
|
|
|
‡a
characterizingpatientswithmultiplechromosomalaberrationsdetectedbyfishinchroniclymphocyticleukemia
‡A
Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia
‡9
1
|
|
919
|
|
|
‡a
chroniclymphocyticleukemiaaclinicalandmolecularheterogenousdisease
‡A
Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
‡9
1
|
|
919
|
|
|
‡a
chroniclymphocyticleukemiapatientswithightranslocationsarecharacterizedbyadistinctgeneticlandscapewithprognosticimplications
‡A
Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications
‡9
1
|
|
919
|
|
|
‡a
crisprcas9generatedmodelsuncovertherapeuticvulnerabilitiesofdel11qcllcellstodualbcrandparpinhibition
‡A
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
‡9
1
|
|
919
|
|
|
‡a
dnadamageresponserelatedalterationsdefinethegeneticbackgroundofpatientswithchroniclymphocyticleukemiaandchromosomalgains
‡A
DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains
‡9
1
|
|
919
|
|
|
‡a
frombiomarkerstomodelsinthechanginglandscapeofchroniclymphocyticleukemiaevolveorbecomeextinct
‡A
From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct
‡9
1
|
|
919
|
|
|
‡a
genomewidetranscriptomicsleadstotheidentificationofderegulatedgenesafterdeferasiroxtherapyinlowriskmdspatients
‡A
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
‡9
1
|
|
919
|
|
|
‡a
genomicdisruptionofthehistonemethyltransferasesetd2inchroniclymphocyticleukaemia
‡A
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.
‡9
1
|
|
919
|
|
|
‡a
hyperdiploidyasarareeventthataccompaniespoorprognosismarkersincll
‡A
Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL.
‡9
1
|
|
919
|
|
|
‡a
identificationofanovelrecurrentgainon20q13inchroniclymphocyticleukemiabyarraycghandgeneexpressionprofiling
‡A
Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling
‡9
1
|
|
919
|
|
|
‡a
imatinibtherapyofchronicmyeloidleukemiarestorestheexpressionlevelsofkeygenesfordnadamageandcellcycleprogression
‡A
Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression
‡9
1
|
|
919
|
|
|
‡a
incidenceandprognosticimpactofsecondarycytogeneticaberrationsinaseriesof145patientswithmantlecelllymphoma
‡A
Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.
‡9
1
|
|
919
|
|
|
‡a
microrna223isanovelnegativeregulatorofhsp90b1incll
‡A
MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL.
‡9
1
|
|
919
|
|
|
‡a
mirnaexpressionprofileofchroniclymphocyticleukemiapatientswith13qdeletion
‡A
MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.
‡9
1
|
|
919
|
|
|
‡a
molecularcharacterizationofchroniclymphocyticleukemiapatientswithahighnumberoflossesin13q14
‡A
Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14.
‡9
1
|
|
919
|
|
|
‡a
nemhesyseuropeanperspectiveontheimplementationofnextgenerationsequencingintoclinicaldiagnostics
‡A
NEMHESYS-European Perspective on the Implementation of Next-generation Sequencing Into Clinical Diagnostics
‡9
1
|
|
919
|
|
|
‡a
nextgenerationsequencingandfishstudiesrevealtheappearanceofgenemutationsandchromosomalabnormalitiesinhematopoieticprogenitorsinchroniclymphocyticleukemia
‡A
Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.
‡9
1
|
|
919
|
|
|
‡a
nextgenerationsequencinginchroniclymphocyticleukemiarecentfindingsandnewhorizons
‡A
Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.
‡9
1
|
|
919
|
|
|
‡a
personalizedmedicineintohealthnationalservicesbarriersandpotentialities
‡A
Personalized medicine into health national services: barriers and potentialities
‡9
1
|
|
919
|
|
|
‡a
pharmacogeneticsandpharmacogenomicsastoolsincancertherapy
‡A
Pharmacogenetics and pharmacogenomics as tools in cancer therapy
‡9
1
|
|
919
|
|
|
‡a
tet2overexpressioninchroniclymphocyticleukemiaisunrelatedtothepresenceoftet2variations
‡A
TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations.
‡9
1
|
|
919
|
|
|
‡a
internationalprognosticindexforpatientswithchroniclymphocyticleukemiahasthehighervalueinpredictingoveralloutcomecomparedwiththebarcelonabrnobiomarkersonlyprognosticmodelandthe1500andersoncancercenterprognosticindex
‡A
The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index
‡9
1
|
|
919
|
|
|
‡a
highnumberoflossesin13q14chromosomebandisassociatedwithaworseoutcomeandbiologicaldifferencesinpatientswithbcellchroniclymphoidleukemia
‡A
A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.
‡9
1
|
|
919
|
|
|
‡a
highproportionofcellscarryingtrisomy12isassociatedwithaworseoutcomeinpatientswithchroniclymphocyticleukemia
‡A
A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia
‡9
1
|
|
996
|
|
|
‡2
NUKAT|n 2012051440
|
|
996
|
|
|
‡2
SUDOC|154448699
|
|
996
|
|
|
‡2
PTBNP|1253575
|
|
996
|
|
|
‡2
PTBNP|1681888
|
|
996
|
|
|
‡2
ISNI|0000000067989280
|
|
996
|
|
|
‡2
NUKAT|n 2014148126
|
|
996
|
|
|
‡2
SUDOC|16840074X
|
|
996
|
|
|
‡2
NUKAT|n 2014050706
|
|
996
|
|
|
‡2
ISNI|0000000077958904
|
|
996
|
|
|
‡2
PTBNP|1235534
|
|
996
|
|
|
‡2
PTBNP|1716280
|
|
996
|
|
|
‡2
BNE|XX4920001
|
|
996
|
|
|
‡2
PTBNP|1381816
|
|
996
|
|
|
‡2
ISNI|0000000070712522
|
|
996
|
|
|
‡2
RERO|A013301485
|
|
996
|
|
|
‡2
RERO|A024890758
|
|
996
|
|
|
‡2
ISNI|000000007092404X
|
|
996
|
|
|
‡2
BNF|16515288
|
|
996
|
|
|
‡2
PTBNP|1001350
|
|
996
|
|
|
‡2
DNB|1073731383
|
|
996
|
|
|
‡2
PTBNP|1378458
|
|
996
|
|
|
‡2
PTBNP|1547723
|
|
996
|
|
|
‡2
PTBNP|1400573
|
|
996
|
|
|
‡2
BLBNB|000385308
|
|
996
|
|
|
‡2
PTBNP|1787360
|
|
996
|
|
|
‡2
PTBNP|952657
|
|
996
|
|
|
‡2
BNE|XX822569
|
|
996
|
|
|
‡2
PTBNP|1529867
|
|
996
|
|
|
‡2
ISNI|000000007293396X
|
|
996
|
|
|
‡2
ISNI|0000000022910209
|
|
996
|
|
|
‡2
NTA|067807372
|
|
996
|
|
|
‡2
SUDOC|254363075
|
|
996
|
|
|
‡2
DNB|172433622
|
|
996
|
|
|
‡2
BNE|XX4981393
|
|
996
|
|
|
‡2
BLBNB|000381793
|
|
996
|
|
|
‡2
BIBSYS|8062942
|
|
996
|
|
|
‡2
SUDOC|203944151
|
|
996
|
|
|
‡2
ISNI|0000000070406728
|
|
996
|
|
|
‡2
ISNI|0000000120323374
|
|
996
|
|
|
‡2
PTBNP|1182759
|
|
996
|
|
|
‡2
ISNI|0000000068272775
|
|
996
|
|
|
‡2
ISNI|0000000116422919
|
|
996
|
|
|
‡2
BNE|XX1723346
|
|
996
|
|
|
‡2
PTBNP|1313295
|
|
996
|
|
|
‡2
PTBNP|26354
|
|
996
|
|
|
‡2
ISNI|0000000070337507
|
|
996
|
|
|
‡2
BNC|981058512088906706
|
|
996
|
|
|
‡2
PTBNP|1392527
|
|
996
|
|
|
‡2
ISNI|0000000069696393
|
|
996
|
|
|
‡2
BNE|XX4617412
|
|
996
|
|
|
‡2
SUDOC|188739645
|
|
996
|
|
|
‡2
PTBNP|1544411
|
|
996
|
|
|
‡2
LC|n 2022252069
|
|
996
|
|
|
‡2
NTA|413391213
|
|
996
|
|
|
‡2
BAV|495_311346
|
|
996
|
|
|
‡2
PTBNP|1809644
|
|
996
|
|
|
‡2
ICCU|BVEV237016
|
|
996
|
|
|
‡2
SUDOC|199737126
|
|
996
|
|
|
‡2
LC|n 83212973
|
|
996
|
|
|
‡2
BNE|XX1800193
|
|
996
|
|
|
‡2
ISNI|0000000071285331
|
|
996
|
|
|
‡2
DNB|138876797
|
|
996
|
|
|
‡2
BNE|XX968350
|
|
996
|
|
|
‡2
PTBNP|1627506
|
|
996
|
|
|
‡2
PTBNP|1188766
|
|
996
|
|
|
‡2
PTBNP|193495
|
|
996
|
|
|
‡2
BNC|981058517988206706
|
|
996
|
|
|
‡2
SUDOC|140201807
|
|
996
|
|
|
‡2
BNE|XX6178035
|
|
996
|
|
|
‡2
SUDOC|061552437
|
|
996
|
|
|
‡2
PTBNP|1660249
|
|
996
|
|
|
‡2
SUDOC|083660992
|
|
996
|
|
|
‡2
LC|no2007081219
|
|
996
|
|
|
‡2
BNE|XX1785384
|
|
996
|
|
|
‡2
ISNI|0000000068091544
|
|
996
|
|
|
‡2
BNE|XX1310419
|
|
996
|
|
|
‡2
LC|n 88013582
|
|
996
|
|
|
‡2
PTBNP|1597315
|
|
996
|
|
|
‡2
ISNI|0000000452761477
|
|
996
|
|
|
‡2
BNF|15006672
|
|
996
|
|
|
‡2
RERO|A016439214
|
|
996
|
|
|
‡2
BNF|16136775
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
